Haematologica, Vol 92, Issue 11, 1533-1548 doi:10.3324/haematol.11185
Copyright © 2007 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schmitz, N.
Right arrow Articles by Sureda, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schmitz, N.
Right arrow Articles by Sureda, A.

Malignant Lymphomas

Allogeneic transplantation in lymphoma: current status

Norbert Schmitz, Peter Dreger, Bertram Glass, Anna Sureda

From the Department of Hematology and Stem Cell Transplantation, ASKLEPIOS Klinik St. Georg, Hamburg, Germany (NS); Department of Medicine V, University of Heidelberg, Germany (PD); Department of Hematology and Oncology, University Hospital Goettingen, Germany (BG); Division of Clinical Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (AS)

Correspondence: Norbert Schmitz, Dept. Hematology and Stem Cell Transplantation, Asklepios Klinik St. Georg, Lohmühlenstr. 5, D-20099 Hamburg, Germany. E-mail: n.schmitz{at}asklepios.com

Allogeneic transplantation of hematopoietic stem cells (allo-SCT) is being increasingly used to treat patients with lymphoma. We describe current results of allo-SCT in patients with Hodgkin’s disease, indolent lymphoma including Waldenström’s disease, and aggressive lymphoma including mantle cell lymphoma and mature T-cell lymphomas. A Graft-vs.-Lymphoma (GvL) effect is present in most entities as evidenced by the generally lower relapse rates after allo-SCT and the results of donor lymphocyte infusions. Slowly proliferating diseases like chronic lymphocytic leukemia, indolent lymphomas, and some T-cell lymphomas are particularly sensitive to the effects of allogeneic T-cells while patients with Hodgkin’s disease and aggressive lymphoma may need vigorous debulking before allo-SCT to achieve optimal results. Although reduced-intensity conditioning has lowered transplant-related mortality in most and improved survival in some sub-entities, relapse rates in patients with Hodgkin’s disease and aggressive B-cell lymphomas, as well as in patients with heavily pre-treated and refractory lymphoma, remain high and further improvement is undoubtedly needed. Large prospective studies in well-defined entities are necessary to further clarify the role of allo-SCT in lymphoma.

Key words: allogeneic stem cell transplantation, Hodgkin’s lymphoma, follicular lymphoma, aggressive lymphoma.




This article has been cited by other articles:


Home page
JCOHome page
J. N. Winter, D. J. Inwards, S. Spies, G. Wiseman, D. Patton, W. Erwin, A. W. Rademaker, B. B. Weitner, S. F. Williams, M. S. Tallman, et al.
Yttrium-90 Ibritumomab Tiuxetan Doses Calculated to Deliver up to 15 Gy to Critical Organs May Be Safely Combined With High-Dose BEAM and Autologous Transplantation in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
J. Clin. Oncol., April 1, 2009; 27(10): 1653 - 1659.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
M. Kornacker, J. Stumm, C. Pott, S. Dietrich, S. Sussmilch, M. Hensel, M. Nickelsen, M. Witzens-Harig, M. Kneba, N. Schmitz, et al.
Characteristics of relapse after autologous stem-cell transplantation for follicular lymphoma: a long-term follow-up
Ann. Onc., April 1, 2009; 20(4): 722 - 728.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
C. A. Rodrigues, G. Sanz, C. G. Brunstein, J. Sanz, J. E. Wagner, M. Renaud, M. de Lima, M. S. Cairo, S. Furst, B. Rio, et al.
Analysis of Risk Factors for Outcomes After Unrelated Cord Blood Transplantation in Adults With Lymphoid Malignancies: A Study by the Eurocord-Netcord and Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
J. Clin. Oncol., January 10, 2009; 27(2): 256 - 263.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
M. R. Bishop, R. M. Dean, S. M. Steinberg, J. Odom, S. Z. Pavletic, C. Chow, S. Pittaluga, C. Sportes, N. M. Hardy, J. Gea-Banacloche, et al.
Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation
Ann. Onc., November 1, 2008; 19(11): 1935 - 1940.
[Abstract] [Full Text] [PDF]